8-K: Intra-Cellular Therapies Announces Positive Phase 3 Results for CAPLYTA in Schizophrenia Relapse Prevention

Intra-Cellular Therapies reports positive topline results from a Phase 3 trial showing CAPLYTA significantly reduces the risk of relapse in schizophrenia patients compared to placebo.

Summary

• Intra-Cellular Therapies has announced positive results from Study 304, a Phase 3 trial evaluating CAPLYTA (lumateperone) for preventing relapse in adults with schizophrenia.
• The study was a randomized withdrawal trial that included an 18-week open-label phase followed by a double-blind phase.
• Patients who were stabilized on lumateperone during the open-label phase were then randomized to either continue on lumateperone or switch to placebo.
• The primary endpoint, time to relapse, was significantly longer in the lumateperone group compared to the placebo group (p=0.0002).
• There were 18 relapses (16.4%) in the lumateperone group and 44 relapses (38.6%) in the placebo group.
• Treatment with lumateperone was associated with a 63% reduction in the risk of relapse compared to placebo (hazard ratio [95% CI] = 0.37, [0.22, 0.65]).
• Lumateperone also met the key secondary endpoint, time to all-cause discontinuation during the double-blind phase (p=0.0007).
• The most common adverse event reported at a rate greater than or equal to 5% and twice the rate of placebo was headache.

Sentiment

Score: 8

Explanation: The document presents very positive clinical trial results with a significant reduction in relapse risk and good tolerability, which is highly favorable for the company and its product. However, there are some risks and warnings that temper the overall sentiment.

Positives

• The study demonstrated a significant reduction in the risk of relapse for patients treated with lumateperone.
• Lumateperone was generally safe and well-tolerated in the study.
• The drug met both the primary and key secondary endpoints of the trial.
• The results support the benefit of continued long-term treatment with lumateperone for schizophrenia.

Negatives

• Headache was the most common adverse event reported at a rate greater than or equal to 5% and twice the rate of placebo.
• The study included a boxed warning regarding increased risk of death in elderly patients with dementia-related psychosis treated with antipsychotic drugs.
• Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adults in short-term studies.

Risks

• There are risks associated with the commercialization of CAPLYTA, including market acceptance and reimbursement challenges.
• The company may encounter unexpected safety or tolerability issues with CAPLYTA.
• There is a risk that a generic equivalent of CAPLYTA could enter the market before the expiration of the company's patents.
• The company's planned supplemental NDA for the treatment of major depressive disorder may not be approved.
• The company relies on collaborative partners and other third parties for the development of its product candidates.
• Global economic uncertainty, inflation, higher interest rates or market disruptions could impact the business.

Future Outlook

The company plans to continue the commercialization of CAPLYTA and pursue further clinical trials for other indications. They are also planning to make regulatory submissions to the FDA.

Management Comments

• Dr. Suresh Durgam, Executive Vice President and Chief Medical Officer of Intra-Cellular Therapies, stated that the results from Study 304 demonstrated efficacy along with favorable safety and tolerability, supporting the benefit of continued long-term treatment with lumateperone.

Industry Context

This announcement is significant for the treatment of schizophrenia, a chronic and serious mental illness. The positive results for CAPLYTA in relapse prevention could position it as a valuable option for long-term management of the condition. This is a competitive space with other antipsychotics, but the efficacy and safety profile of CAPLYTA could give it an advantage.

Comparison to Industry Standards

• The 63% reduction in relapse risk with lumateperone is a strong result compared to many other antipsychotics used for maintenance treatment of schizophrenia.
• Many older antipsychotics have significant side effects, so the favorable safety and tolerability profile of CAPLYTA is a positive differentiator.
• Other companies such as Janssen (Invega), Otsuka (Abilify), and Alkermes (Aristada) also have long-acting injectable antipsychotics for maintenance treatment, but CAPLYTA is an oral option which may be preferred by some patients.
• The study design, a randomized withdrawal trial, is a standard approach for evaluating maintenance treatments in schizophrenia.

Stakeholder Impact

• Shareholders will likely react positively to the strong clinical trial results.
• Patients with schizophrenia may benefit from a new treatment option for relapse prevention.
• Physicians may be more likely to prescribe CAPLYTA based on these results.
• Employees of Intra-Cellular Therapies may be positively impacted by the success of the clinical trial.

Next Steps

• The company will likely pursue regulatory submissions based on these results.
• They will continue to monitor the safety and efficacy of CAPLYTA in ongoing and future trials.
• The company will continue the commercialization of CAPLYTA for its approved indications.

Key Dates

Keywords

CAPLYTA, lumateperone, schizophrenia, relapse prevention, clinical trial, CNS disorders, antipsychotic, mental illness, Phase 3, biopharmaceutical